HB 2200 Virginia House of Delegates · 2023 Regular Session

Anti-cancer drugs; analyzing current reimbursement, etc., for medical practices that administer.

Bill status signed all 5 stages cleared

Introduction

Jan 2023

Committee Review

Feb 2023

House of Delegates Passage

Mar 2023

Senate Passage

Mar 2023

Signed into Law

Mar 2023

Introduced Jan 11, 2023 Signed Mar 26, 2023

Floor votes

How they voted

This bill passed the Senate by voice vote (no roll call recorded).

Full legislative history

Actions timeline

Total actions

Key actions

Committee

Mar 26, 2023

Signed into law

Approved by Governor-Chapter 582 (effective 7/1/23)

executive

Mar 8, 2023

Upper · Passed

Signed by President

upper

Mar 8, 2023

Lower · Passed

Signed by Speaker

lower

Mar 7, 2023

Lower · Passed

Bill text as passed House and Senate (HB2200ER)

lower

Feb 21, 2023

Upper · Passed

Passed Senate with substitute (40-Y 0-N)

upper

Feb 16, 2023

Upper · Passed

Senate committee, floor amendments and substitutes offered

upper

Feb 16, 2023

Upper · Passed

Reported from Finance and Appropriations with substitute (16-Y 0-N)

upper

Feb 8, 2023

Committee

Referred to Committee on Finance and Appropriations

upper

Feb 7, 2023

Lower · Passed

VOTE: Passage (63-Y 35-N)

lower

Feb 7, 2023

Lower · Passed

Read third time and passed House (63-Y 35-N)

lower

Feb 1, 2023

Lower · Passed

Reported from Finance (14-Y 8-N)

lower

Jan 30, 2023

Lower · Passed

Subcommittee recommends reporting (6-Y 0-N)

lower

Jan 26, 2023

Committee

Assigned Finance sub: Subcommittee #3

lower

Jan 11, 2023

Committee

Referred to Committee on Finance

lower

1 primary · 0 co-sponsors